Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Péptido para control del cáncer ligado a sobreexpresión de IL13Ra2

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20180117001
Publicado:
03/04/2018
Caducidad:
04/04/2019
Resumen:
Un centro español de investigación pública ha desarrollado un péptido capaz de inhibir la señalización de interleucina 13 mediada por el receptor de interleucina 13. Este péptido sintético solo o encapsulado en una nanopartícula o partículas virales puede utilizarse en una composición farmacéutica para el tratamiento de patologías en las que el receptor IL13Ra2 está sobreexpresado: control de metástasis de cáncer de colon y otros tumores (por ejemplo, glioblastoma), asma, dermatitis atópica o fibrosis. El centro de investigación busca socios industriales para establecer acuerdos de licencia.

Details

Tittle:
Peptide for cancer control linked to IL13Ra2 overexpression
Summary:
A Spanish Research Public Organization has developed a peptide capable of inhibiting the signaling of Interleukin 13 mediated by interleukin 13 receptor The peptide alone or within a nanoparticle or virus-like particles can be used in a pharmaceutical composition for the treatment of pathologies in which it is overexpressed: control of metastasis of colon cancer and other tumors (i.e glioblastoma), asthma, atopic dermatitis or fibrosis. Industrial partners are being sought for licence agreement.
Description:
Recent studies have identified a pro-metastatic role for human interleukin 13 (IL-13) in colorectal cancer mediated through the interleukin 13 receptor a2 (IL13Ra2). The binding of IL-13 to IL13Ra2 triggers different cellular pathways to promote migration, invasion and survival of the metastatic cells. In addition, IL13Ra2 is overexpressed in a variety of human tumor types such as glioblastoma, renal cell carcinoma, pancreatic, melanoma, head and neck, mesothelioma and ovarian, where it has been proposed as biomarker and potential therapeutic target.
There is a need for improved strategies for treating tumors and other diseases where IL13Ra2 is expressed, like glioblastoma and metastatic colorectal cancer.
The authors have found a peptide that is capable of inhibiting IL13/IL13Ra2 signaling. They have also developed a fusion protein with the peptide and at least a heterologous polypeptide. Both can be introduced in a nanoparticle or virus-like particle to be included in a pharmaceutical composition to be used in cancer and metastasis control when IL13Ra2 is overexpressed. Besides this composition can be applied to other pathologies related with IL13Ra2 such as asthma, atopic dermatitis or fibrosis.

The Spanish research group has a broad experience in developing novel compounds to be tested as potential candidates to treat colon cancer.

The Spanish research centre is searching for a company interested in the developement and commerzialization of these novel compounds under a license agreement. The compounds have only been tested at a laboratory scale, therefore some further development might be needed and the Spanish research centre could collaborate with the company in that project.
Advantages and Innovations:
A new strategy for the treatment of cancer is presented related to IL13 / IL13Ra2 and the derived metastases

Peptides and derivative pharmaceutical compositions can be applied to other pathologies of high incidence
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Spanish patent application

Partner sought

Type and Role of Partner Sought:
Industrial partners are being sought to develop and commercialize the compounds through a patent licence agreement.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001003 Citología, cancerología, oncología
06001012 Investigaciones médicas
06001015 Productos farmacéuticos / medicamentos